2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

2018 Circulation 655 citations

Abstract

This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the US Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials intended to support marketing applications. The writing committee recognizes that these definitions may be used in other types of clinical trials and clinical care processes where appropriate. Use of these definitions at the FDA has enhanced the ability to aggregate data within and across medical product development programs, conduct meta-analyses to evaluate cardiovascular safety, integrate data from multiple trials, and compare effectiveness of drugs and devices. Further study is needed to determine whether prospective data collection using these common definitions improves the design, conduct, and interpretability of the results of clinical trials.

Keywords

MedicineClinical trialData collectionFood and drug administrationInterpretabilityAlternative medicineStroke (engine)Clinical study designClinical researchAggregate dataResearch designMEDLINEMedical physicsIntensive care medicineRisk analysis (engineering)PathologyArtificial intelligenceComputer science

Affiliated Institutions

Related Publications

Publication Info

Year
2018
Type
review
Volume
137
Issue
9
Pages
961-972
Citations
655
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

655
OpenAlex

Cite This

Karen A. Hicks, Kenneth W. Mahaffey, Roxana Mehran et al. (2018). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation , 137 (9) , 961-972. https://doi.org/10.1161/circulationaha.117.033502

Identifiers

DOI
10.1161/circulationaha.117.033502